权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Clinical Core

临床核心

基本信息

批准号：
9322488
负责人：
MARC A SIMON
金额：
$ 40.35万
依托单位：
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
依托单位国家：
美国
项目类别：
财政年份：
资助国家：
美国
起止时间：
至
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/9322488
关键词：
Address Animals Arteries Blood Blood Vessels Blood capillaries Blood specimen Cardiac Catheterization Procedures Categories Center for Translational Science Activities Chronic Chronic Obstructive Airway Disease Clinic Clinical Clinical Data Clinical Trials Collection Complex Conduct Clinical Trials Conjugated Linoleic Acids DNA Data Development Disease EFRAC Enrollment Etiology Fatty Acids Feces Fibroblasts Funding Goals HIV Infections Harvest Heart Diseases Heart failure Housing Human Hypoxemia Individual Industry Investigation Investigational Therapies Investments Left Link Lung Lung Transplantation Lung diseases Metabolic Metabolic syndrome Muscle Cells Nitrites Oral Outcome Pathogenesis Pathway interactions Patients Phase Phenotype Plasma Population Publications Pulmonary Hypertension Pulmonary artery structure RNA Recruitment Activity Registries Research Infrastructure Research Personnel Research Project Grants Resources Risk Risk Factors Role Sampling Smooth Muscle Subgroup Systemic disease Testing Therapeutic Therapeutic Intervention Time Translational trial Transplantation Treatment outcome United States National Institutes of Health Vascular Smooth Muscle Venous base biobank capillary clinical biomarkers clinical infrastructure dietary supplements hemodynamics improved insight microbiome novel therapeutic intervention novel therapeutics patient population patient registry personalized medicine pressure programs pulmonary arterial hypertension pulmonary artery endothelial cell response screening therapeutic target translational clinical trial treatment response treatment trial

项目摘要

Clinical Core Abstract The human core developed through the first 4 years has become an established center for translational research in pulmonary hypertension (PH), encompassing a large biorepository and clinical trials coordinating center. The goal of the human core during this renewal is to support all Research Projects by 1) providing the infrastructure and expertise necessary to conduct clinical trials of new therapies of dietary supplements for Group I and Group II PH, and 2) collecting hemodynamic, clinical, biomarker, and microbiome data on PH patients for robust phenotyping. Specific expansions of the human core for this renewal include enrollment of Groups I-V PH patients into the human subphenotyping core registry to provide mechanistic insight into endo- phenotypes of PH including the role of the microbiome in PH, collection of pulmonary artery endothelial cells during clinical right heart catheterization, as well as harvest of isolated endothelial, smooth muscle and lung fibroblasts from human lungs of PH patients removed at time of transplantation. The core will draw on the extensive clinical and research infrastructure harnessed during the first phase of the TPPG including 14 clinics, over 1,000 clinical right heart catheterization each year, 34 ongoing NIH- or industry-funded research projects, over 2,500 biospecimens banked, a vascular clinical translational research center specializing in assessment of endothelial function for 9 NIH- or industry-funded research projects, and over 1,200 patients enrolled in clinical trials over the past five years. The human core is critical to all Projects to fulfill the translational directive of the TPPG, in which each Project will conduct a clinical or translational trial. This unmatched resource will accelerate the pace of discovery in the Projects by rapidly identifying appropriate patients for clinical trials and by providing a wealth of biospecimens with corresponding clinical data for mechanistic investigations.

临床核心摘要